Company news

BioAge Labs, Inc. news in 2026

BioAge Labs, Inc.'s news releases, calls and decks from 2026, newest first.

View company

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

November 5, 2026

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

September 8, 2026

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 5, 2026

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

July 14, 2026

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

June 16, 2026

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026

R&D Day Presentation

May 7, 2026

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

May 4, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

April 21, 2026

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

April 13, 2026

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

March 23, 2026

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

February 9, 2026

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

January 21, 2026

BioAge Announces Proposed Public Offering

January 20, 2026

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

January 20, 2026

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

January 12, 2026

Decks in 2026